Real-Time PCR Detection Kit for Avian Influenza Virus H5/H7/H9/Universal Subtype

Product Description

Detection Kit for Avian Influenza Virus H5/H7/H9/Universal Subtype RNA(PCR-Fluorescence Probing)
(Product Name) Detection Kit for Avian Influenza Virus H5/H7/H9/Universal Subtype RNA(PCR-Fluorescence Probing)
(Package) 50 kits/box
(Indication) The Detection Kit for Avian Influenza Virus H5/H7/H9/Universal RNA(PCR-Fluorescence Probing) is applicable to detect the Avian Influenza virus H5/H7/H9/Universal RNA in avian throat swab, cloaca swab, tissue, chicken embryo allantoic fluid and cell culture. The test results are for research purpose only and not for clinical diagnosis.
(Main components and content)

Name	Specification	Quantity
H5/H7/H9/Universal Trivalent Reaction Solution	1250µl/Tube	1
H5/H7/H9/Universal Positive Control	250µl/Tube	1
Negative Control	250µl/Tube	1

(Storage and Shelf Life)
Stored at -20±5ºC,Repeated freezing and thawing ≤ 3 times, the shelf life is 12 months.
(Model)
ABI 7500, ABI QuantStudio 5, CFX Connect, CFX Opus 96, LightCycler480, Gentiter 96E/96R, LineGene 9600 Plus and other fluorescent quantitative PCR amplifier.
(Test Method) Nucleic Acid Extraction Commercialized RNA extraction kit can be carried out for nucleic acid extraction, please follow the instruction of the kit. PCR amplification 2.1 Calculate the number of test samples, take n+2 PCR reaction tubes, and add 25µl to of reaction solution to each tube.
2.2 Add 5µl nucleic acid of negative control, positive control and samples into the above PRC reaction tubes respectively, centrifuge at 8000rpm for several seconds, and put them into the fluorescent quantitative PCR amplifier..
2.3 The reaction conditions are set as follows:

Relevant parameters of the amplifier
System	Total volume: 30µl
Signal collection	Avian Influenza H5/H7/H9/Universal	H5 subtype - HEX channel collects fluorescence signal
		H7 subtype - FAM channel collects fluorescence signal
		H9 subtype - Cy5 channel collects fluorescence signal
		Universal - ROX channel collects fluorescence signal
PCR reaction conditions	Stage	Condition	Cycle number
	Reverse Transcription	55ºC: 15 minutes	1
	Predegeneration	95ºC: 30 seconds	1
	PCR	95ºC: 10 seconds	40
		56ºC: 30 seconds (Set to collect fluorescent signal at the end of this stage)

(Interpretation of the results) Determination of test kit effectiveness : Weak positive control: Ct value of FAM, HEX,Cy5 and ROX channels ≤ 32, amplification curve with obvious exponential phase. Blank control: FAM, HEX, Cy5 and ROX channels have no amplification curve, or the amplification curve is straight or slight oblique, no significant exponential phase, and Ct value ≥ 38 or no Ct value. Determination of the results:

Result Judgement	FAM channel	HEX channel	Cy5 channel	ROX channel
Avian influenza virus H5 subtype nucleic acid positive	-	+	-	+
Avian influenza virus H7 subtype nucleic acid positive	+	-	-	+
Avian influenza virus H9 subtype nucleic acid positive	-	-	+	+
Avian influenza virus H5/H7 nucleic subtype acid positive	+	+	-	+
Avian influenza virus H5/H9 nucleic subtype acid positive	-	+	+	+
Avian influenza virus H7/H9 nucleic subtype acid positive	+	-	+	+
Avian influenza virus H5/H7/H9 nucleic subtype acid positive	+	+	+	+
Low pathogenic avian influenza virus nucleic acid positive	-	-	-	+
Avian influenza virus nucleic acid negative	-	-	-	-

*Note: If there is a logarithmic growth phase amplification curve and Ct value ≤ 36, it is judged as +. If there is no amplification curve or Ct value > 36, it is judge as -. The samples are suspicious when 36 < Ct value <40, which has to be retested. If the results of any H5/H7/H9 subtype is + with ROX channel -, which has to be retested. (Precautions) The laboratory management shall be in strict accordance with the management specification of PCR gene amplification laboratory. The laboratory personnel must be trained professionally. The experiment process shall be conducted strictly in different areas (Reagent preparation area, specimen preparation area, amplification and product analysis area). All consumables shall be disposable after sterilization. Special apparatus, equipment and supplies at each stage of the experiment operation shall not be cross-used. Please prepare the biological safety cabinet for reagent and specimen preparation stage. The Lab coat, disposable gloves and pipettor shall be carried out during the experiment. Repeated freezing&thawing of reagents shall be avoided as far as possible. Before use, the reagents shall be completely thawed and centrifuged at 8000rpm for several seconds. Please put the pipette used in the specimen preparation area into the container containing disinfectant and discard with the waste after sterilization. After the experiment, the worktable and pipettor were treated with 10% hypochlorite or 75% alcohol or ultraviolet lamp.
(Manufacture)
Name: Shandong Xinda Gene Technology Co., Ltd
A subsidiary of the Shandong Sinder Technology Co., Ltd
Address: Building B2, Bandaohuigu Industrial Park, Shungeng Road, Zhucheng City, Shandong Province
Shandong Sinder Technology Co., Ltd ('Sinder') founded in April 1999, has a wide range of animal health products. Sinder focus on Animal Health Products, Animal Vaccine, Antibodies, Antibiotics, Feed Additives, Chinese Herbal Product, Pet food, Elisa, and PCR test kit.
Sinder always persists in the core concept of 'The Relentless Pursuit of Increasing Customer Value. ' Based on the animal health to achieve a service provider for ecological construction of agriculture and animal husbandry. Support the efficient and sustainable development of agriculture and animal husbandry. Make food safer and rural areas better!
Sinder is a high-tech enterprise and one of the top 10 veterinary drug manufacturers in China and focusing on the animal health business. At the moment, the company has 35 GMP production lines, 1 CNAS laboratory, 3 national scientific research platforms, and 8 provincial scientific research platforms owned by Sinder.
Sinder has 4 R&D centers located in Qingdao, Zhucheng, and Beijing, China, and 1 laboratory in Silicon Valley in the United States. At present, the company has 1,535 employees including more than 200 masters or above and 18 doctors. Also, the company established extensive technical cooperation with several domestic and foreign scientific research institutes, animal health companies, and domestic veterinary medicine enterprises. Sinder has undertaken 57 national, provincial, and ministerial projects, gained 7 provincial and ministerial science and technology progress awards, presided over or participated in 23 national standards, obtained 23 new veterinary drug certificates(one 1st class new drug), and 60 authorized patents.